24/7 Market News Snapshot 23 June, 2025 – Genprex, Inc. Common Stock (NASDAQ:GNPX)

June 23, 2025

DENVER, Colo., 23 June, 2025 (www.247marketnews.com) – (NASDAQ:GNPX) are discussed in this article.
Genprex, Inc. is witnessing a significant surge in investor interest, with its stock trading at $0.312 in the pre-market session, marking an 18.23% increase from the previous close of $0.264. The trading volume has reached 24.72 million shares, a clear indicator of heightened market activity and momentum. This notable price movement suggests a potential continuation of the upward trend, particularly if the stock surpasses established resistance levels. Traders are advised to keep a close watch on essential technical indicators such as the relative strength index (RSI) and moving averages to gauge possible overbought conditions or to confirm further bullish sentiments. GNPX represents a compelling short-term investment opportunity within the biotech sector.

In tandem with the promising market performance, Genprex has announced pivotal advancements in its diabetes gene therapy research. The firm recently showcased groundbreaking preclinical data on its innovative GPX-002 drug candidate at the prestigious American Diabetes Association’s 85th Scientific Sessions. This cutting-edge research, conducted in collaboration with industry leaders, utilizes a novel non-viral lipid nanoparticle delivery system, aiming to revolutionize treatment options for both Type 1 and Type 2 diabetes through potential repeat dosing.

Significantly, the research highlighted the efficacy of nine lipid nanoparticles in transfecting pancreatic cells, with specific formulations achieving remarkable transfection rates in mouse Islets of Langerhans. Ryan Confer, President and CEO of Genprex, emphasized that this pioneering approach could enhance patient treatment options while simplifying administration processes via routine endoscopic procedures. The lipid nanoparticles demonstrated notable specificity for pancreatic cells, exhibiting up to 100 times greater activity compared to other organs, which may reduce the need for immunosuppression in current treatments. As Genprex’s work on GPX-002 progresses, the potential to transform diabetes management continues to grow, promising innovative solutions tailored to the needs of patients.

Related news for (GNPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.